Price Alert

Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM · Real-Time Price · USD

17.64

0.12 (0.68%)

At close: Aug 14, 2025, 3:59 PM

17.74

0.57%

After-hours: Aug 14, 2025, 07:53 PM EDT

0.68% (1D)

Bid	17.22
Market Cap	1.78B
Revenue (ttm)	60.27M
Net Income (ttm)	-398.58M
EPS (ttm)	-4.5
PE Ratio (ttm)	-3.92
Forward PE	-3.95
Analyst	Buy

Ask	17.79
Volume	3,227,882
Avg. Volume (20D)	2,476,589.6
Open	17.56
Previous Close	17.52
Day's Range	17.04 - 18.23
52-Week Range	13.53 - 35.25
Beta	2.23

About BEAM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BEAM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BEAM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Beam Therapeutics has released their quartely earnings on Aug 5, 2025:

Revenue of $8.47M misses estimates by $5.02M, with -28.08% YoY decline.

EPS of -1 exceeds estimates by 0.07, with 9.91% YoY growth.

Next Earnings Release

Beam Therapeutics Inc. is scheduled to release its earnings on Nov 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

+0.63%

BEAM stock has given up its prior gain. Beam Thera... Unlock content with Pro Subscription

1 day ago New

+0.63%

Beam Therapeutics shares are trading higher after the company announced the FDA has granted regenerative medicine advanced therapy designation status for Beam-101.

News

1 week ago · zacks.com

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.

1 week ago · zacks.com

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.

2 weeks ago · zacks.com

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?

Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

1 month ago · fool.com

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

1 month ago · zacks.com

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

1 month ago · schaeffersresearch.com

Top Stock Pick Report: V-Shaped Rallies Everywhere

Subscribers to Chart of the Week received this commentary on Sunday, June 22.

1 month ago · seekingalpha.com

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from p...

2 months ago · zacks.com

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

2 months ago · zacks.com

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.